Q32 BIO INCORPORATED (QTTB)

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Q32 Bio (QT…

Q32 Bio is selling 6.0M shares at $18.25 plus 4.9M pre-funded warrants, targeting $187.6M–$215.8M in net proceeds to fund R&D and bempikibart trials.

The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... On July 14, 2026, the latest public offering for Q32 Bio Inc QTTB has been set at a price lower than its last trading value of $18.46.

/PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata...